Shanghai Junshi Biosciences Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Junshi Biosciences Co., Ltd.
BeiGene co-founder and chair of the major global biotech's Scientific Advisory Board, Dr. Xiaodong Wang, sits down with Scrip in an exclusive audio interview to shed light on the rapid rise of China's biotech innovation, the country's role in BeiGene's global strategy and the next big things to watch.
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
After years of laying the foundations, China Biotech Inc. is being pursued by multinationals looking for innovative candidates to commercialize in both China and globally, executives and deals from the just concluded J.P Morgan Global Healthcare Conference show.
Companies from China single-handedly sponsored a total of eight Phase III clinical studies that included US sites in 2023 compared to six in 2022 - but the figure was still below the record of 11 in 2021.
- Large Molecule
- Other Names / Subsidiaries
- Junshi Biosciences
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.